cis-Dichlorodiammineplatinum(II) and DTIC in malignant melanoma.

Twenty-nine patients with advanced malignant melanoma were randomized to receive DTIC at a dose of 200 mg/m2 iv on Days 1-5 and cis-dichlorodiammine-platinum(II) at a dose of 40 mg/m2 iv on Days 1 and 4, repeated every 4 weeks (group A), or the same drugs plus procarbazine at a dose of 75 mg/m2 orally daily on Days 1-8 and vincristine at a dose of 1.4 mg/m2 iv on Day 1 (group B). These drugs were generally well-tolerated, but five of 16 patients in group A and six of 13 patients in group B required dose modification for either hematologic or renal toxicity. There were six objective responses among 16 patients in group A including one complete regression, while there were two objective responses among 13 patients in group B.